Skip to content
DataLookout
Menu

NCT05463952

A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)

StatusUnknown
PhasePhase 1
SponsorPfizer
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 8 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
  2. Minor Study completion date: Sep 30, 2024 to Mar 31, 2025v10
  3. Notable Results first posted: Sep 23, 2024v9 Show 5 more changesShow less
    • Primary endpoint revised
    • Study completion date: Mar 31, 2024 to Sep 30, 2024
    • Interventions: ARV-471 (Drug) to vepdegestrant (Drug)
    • Secondary endpoints: 25 to 20
    • Study title expanded, about 1 word
  4. Minor Primary completion date changed from estimate of Apr 19, 2023 to May 4, 2023
    • Study completion date: Apr 19, 2023 to Mar 31, 2024
    v6
  5. Notable Eligibility criteria expanded, about 12 wordsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 9 to confirmed 6
    • Site details revised at 3 of 3 sites
    • Collaborator revised
    v4
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 17, 2022 to Aug 16, 2022
    • Site details revised at 3 of 3 sites
    v3
  3. Minor Study sites: 0 to 3v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants With Dose Limiting Toxicity (DLTs) During First Treatment Cycle
Timeframe: Cycle 1 (28 days)

Secondary (20)

Number of Participants With AEs and Serious AEs (SAEs)- All Causalities and Treatment Related
Number of Participants With Laboratory Hematology Results by Maximum National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Grade
Number of Participants With Laboratory Chemistry Results by Maximum NCI-CTCAE Grade
Area Under the Plasma Concentration-Time Curve From Time Zero to Time Tau (AUCtau) of ARV 471 and ARV-473
Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of ARV-471 and ARV-473
Show 15 moreShow less
Maximum Observed Plasma Concentration (Cmax) of ARV-471 and ARV-473
Time to Reach Maximum Concentration (Tmax) of ARV-471 and ARV-473
Terminal Elimination Half-Life (t1/2) of ARV-471 and ARV-473
Metabolite Ratio for Cmax (MRCmax)
Metabolite Ratio for AUCtau (MRAUCtau)
Lowest Concentration Observed During the Dosing Interval (Cmin) of ARV-471 and ARV-473
Pre-dose Plasma Concentration (Ctrough) of ARV-471 and ARV-473
Apparent Total Clearance (CL/F) of ARV-471
Apparent Volume of Distribution (Vz/F) of ARV-471
Effective Half-Life Based on Accumulation Ratio (t½Eff) of ARV-471 and ARV-473
Accumulation Ratio (Rac) Based on AUC of ARV-471 and ARV-473
Objective Response Rate (ORR)
Clinical Benefit Response (CBR)
Progression Free Survival (PFS)
Duration of Response (DOR)

Arms and interventions

vepdegestrantExperimental

Daily oral dosages of vepdegestrant

Drugs: vepdegestrant

Sites

3 sites in 1 country